Report Content
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates and working
1.2.1 North America
1.2.2 Europe
1.2.3 Asia Pacific
1.2.4 Latin America
1.2.5 Middle East and Africa (MEA)
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Antidepressant drugs industry 3600 synopsis, 2016 – 2027 (USD Million)
2.1.1 Business trends
2.1.2 Drug class trends
2.1.3 Application trends
2.1.4 Regional trends
Chapter 3 Antidepressant drugs Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 – 2027 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising prevalence of depression and anxiety disorders
3.3.1.2 Increasing investment in research and development
3.3.1.3 Growing awareness regarding treatment therapies and mental health
3.3.2 Industry pitfalls & challenges
3.3.2.1 Side effects associated with some antidepressant drugs
3.3.2.2 Customer preference for non-pharmacological therapeutics over pharmacological therapeutics
3.4 Growth potential analysis
3.4.1 By drug class
3.4.2 By application
3.5 COVID-19 impact analysis
3.6 Prescription pattern analysis
3.6.1 By gender
3.6.2 By Age group
3.7 Porter’s analysis
3.8 Competitive landscape, 2020
3.9 PESTEL analysis
Chapter 4 Antidepressant Drugs Market, By Drug Class
4.1 Key segment trends
4.2 Selective serotonin reuptake inhibitors (SSRIs)
4.2.1 Market size by region, 2016 – 2027 (USD Million)
4.3 Serotonin-norepinephrine reuptake inhibitors (SNRIs)
4.3.1 Market size by region, 2016 – 2027 (USD Million)
4.4 Tricyclic antidepressants
4.4.1 Market size by region, 2016 – 2027 (USD Million)
4.5 Others
4.5.1 Market size by region, 2016 – 2027 (USD Million)
Chapter 5 Antidepressant Drugs Market, By Application
5.1 Key segment trends
5.2 Major depressive disorder
5.2.1 Market size by region, 2016 – 2027 (USD Million)
5.3 Obsessive-compulsive disorder
5.3.1 Market size by region, 2016 – 2027 (USD Million)
5.4 Generalized anxiety disorder
5.4.1 Market size by region, 2016 – 2027 (USD Million)
5.5 Panic disorder
5.5.1 Market size by region, 2016 – 2027 (USD Million)
5.6 Others
5.6.1 Market size by region, 2016 – 2027 (USD Million)
Chapter 6 Antidepressant Drugs Market, By Region
6.1 Key regional trends
6.2 North America
6.2.1 Market size by country, 2016 – 2027 (USD Million)
6.2.2 Market size by drug class, 2016 – 2027 (USD Million)
6.2.3 Market size by application, 2016 – 2027 (USD Million)
6.2.4 U.S.
6.2.4.1 Market size by drug class, 2016 – 2027 (USD Million)
6.2.4.2 Market size by application, 2016 – 2027 (USD Million)
6.2.5 Canada
6.2.5.1 Market size by drug class, 2016 – 2027 (USD Million)
6.2.5.2 Market size by application, 2016 – 2027 (USD Million)
6.3 Europe
6.3.1 Market size by country, 2016 – 2027 (USD Million)
6.3.2 Market size by drug class, 2016 – 2027 (USD Million)
6.3.3 Market size by application, 2016 – 2027 (USD Million)
6.3.4 Germany
6.3.4.1 Market size by drug class, 2016 – 2027 (USD Million)
6.3.4.2 Market size by application, 2016 – 2027 (USD Million)
6.3.5 UK
6.3.5.1 Market size by drug class, 2016 – 2027 (USD Million)
6.3.5.2 Market size by application, 2016 – 2027 (USD Million)
6.3.6 France
6.3.6.1 Market size by drug class, 2016 – 2027 (USD Million)
6.3.6.2 Market size by application, 2016 – 2027 (USD Million)
6.3.7 Spain
6.3.7.1 Market size by drug class, 2016 – 2027 (USD Million)
6.3.7.2 Market size by application, 2016 – 2027 (USD Million)
6.3.8 Italy
6.3.8.1 Market size by drug class, 2016 – 2027 (USD Million)
6.3.8.2 Market size by application, 2016 – 2027 (USD Million)
6.3.9 Turkey
6.3.9.1 Market size by drug class, 2016 – 2027 (USD Million)
6.3.9.2 Market size by application, 2016 – 2027 (USD Million)
6.3.10 Sweden
6.3.10.1 Market size by drug class, 2016 – 2027 (USD Million)
6.3.10.2 Market size by application, 2016 – 2027 (USD Million)
6.4 Asia Pacific
6.4.1 Market size by country, 2016 – 2027 (USD Million)
6.4.2 Market size by drug class, 2016 – 2027 (USD Million)
6.4.3 Market size by application, 2016 – 2027 (USD Million)
6.4.4 China
6.4.4.1 Market size by drug class, 2016 – 2027 (USD Million)
6.4.4.2 Market size by application, 2016 – 2027 (USD Million)
6.4.5 India
6.4.5.1 Market size by drug class, 2016 – 2027 (USD Million)
6.4.5.2 Market size by application, 2016 – 2027 (USD Million)
6.4.6 Japan
6.4.6.1 Market size by drug class, 2016 – 2027 (USD Million)
6.4.6.2 Market size by application, 2016 – 2027 (USD Million)
6.4.7 Australia
6.4.7.1 Market size by drug class, 2016 – 2027 (USD Million)
6.4.7.2 Market size by application, 2016 – 2027 (USD Million)
6.4.8 South Korea
6.4.8.1 Market size by drug class, 2016 – 2027 (USD Million)
6.4.8.2 Market size by application, 2016 – 2027 (USD Million)
6.4.9 New Zealand
6.4.9.1 Market size by drug class, 2016 – 2027 (USD Million)
6.4.9.2 Market size by application, 2016 – 2027 (USD Million)
6.5 Latin America
6.5.1 Market size by country, 2016 – 2027 (USD Million)
6.5.2 Market size by drug class, 2016 – 2027 (USD Million)
6.5.3 Market size by application, 2016 – 2027 (USD Million)
6.5.4 Brazil
6.5.4.1 Market size by drug class, 2016 – 2027 (USD Million)
6.5.4.2 Market size by application, 2016 – 2027 (USD Million)
6.5.5 Mexico
6.5.5.1 Market size by drug class, 2016 – 2027 (USD Million)
6.5.5.2 Market size by application, 2016 – 2027 (USD Million)
6.5.6 Argentina
6.5.6.1 Market size by drug class, 2016 – 2027 (USD Million)
6.5.6.2 Market size by application, 2016 – 2027 (USD Million)
6.6 Middle East & Africa
6.6.1 Market size by country, 2016 – 2027 (USD Million)
6.6.2 Market size by drug class, 2016 – 2027 (USD Million)
6.6.3 Market size by application, 2016 – 2027 (USD Million)
6.6.4 South Africa
6.6.4.1 Market size by drug class, 2016 – 2027 (USD Million)
6.6.4.2 Market size by application, 2016 – 2027 (USD Million)
6.6.5 Saudi Arabia
6.6.5.1 Market size by drug class, 2016 – 2027 (USD Million)
6.6.5.2 Market size by application, 2016 – 2027 (USD Million)
Chapter 7 Company Profiles
7.1 Competitive dashboard, 2020
7.2 Eli Lilly & Company
7.2.1 Business overview
7.2.2 Financial data
7.2.3 Product landscape
7.2.4 Strategic outlook
7.2.5 SWOT analysis
7.3 Pfizer
7.3.1 Business overview
7.3.2 Financial data
7.3.3 Product landscape
7.3.4 Strategic outlook
7.3.5 SWOT analysis
7.4 Bristol Myers Squibb
7.4.1 Business overview
7.4.2 Financial data
7.4.3 Product landscape
7.4.4 Strategic outlook
7.4.5 SWOT analysis
7.5 GlaxoSmithKline Plc.
7.5.1 Business overview
7.5.2 Financial data
7.5.3 Product landscape
7.5.4 Strategic outlook
7.5.5 SWOT analysis
7.6 Patheon Inc.
7.6.1 Business overview
7.6.2 Financial data
7.6.3 Product landscape
7.6.4 Strategic outlook
7.6.5 SWOT analysis
7.7 Sandoz Inc.
7.7.1 Business overview
7.7.2 Financial data
7.7.3 Product landscape
7.7.4 Strategic outlook
7.7.5 SWOT analysis
7.8 N.V. Organon
7.8.1 Business overview
7.8.2 Financial data
7.8.3 Product landscape
7.8.4 Strategic outlook
7.8.5 SWOT analysis
7.9 Takeda Pharmaceuticals
7.9.1 Business overview
7.9.2 Financial data
7.9.3 Product landscape
7.9.4 Strategic outlook
7.9.5 SWOT analysis
7.10 Zhejiang NHU company Ltd.
7.10.1 Business overview
7.10.2 Financial data
7.10.3 Product landscape
7.10.4 Strategic outlook
7.10.5 SWOT analysis
7.11 Sun Pharmaceuticals Pvt. Ltd
7.11.1 Business overview
7.11.2 Financial data
7.11.3 Product landscape
7.11.4 Strategic outlook
7.11.5 SWOT analysis
7.12 Intracellular Therapies
7.12.1 Business overview
7.12.2 Financial data
7.12.3 Product landscape
7.12.4 Strategic outlook
7.12.5 SWOT analysis
7.13 Otsuka Pharmaceuticals
7.13.1 Business overview
7.13.2 Financial data
7.13.3 Product landscape
7.13.4 Strategic outlook
7.13.5 SWOT analysis
7.14 Janssen Pharmaceuticals (Johnson & Johnson)
7.14.1 Business overview
7.14.2 Financial data
7.14.3 Product landscape
7.14.4 Strategic outlook
7.14.5 SWOT analysis
7.15 Novartis AG
7.15.1 Business overview
7.15.2 Financial data
7.15.3 Product landscape
7.15.4 Strategic outlook
7.15.5 SWOT analysis
7.16 Opko health
7.16.1 Business overview
7.16.2 Financial data
7.16.3 Product landscape
7.16.4 Strategic outlook
7.16.5 SWOT analysis
